Also found in: Medical.
BSABBoth Sides Are Bad
BSABBellshill Salvation Army Band (UK)
BSABBalthazar Scales of Adaptive Behavior (intelligence quotient test)
BSABBody Surface Area Burn
BSABBachelor of Science in Applied Biotechnology (University of Georgia)
BSABByggandets Samordning Aktiebolag (Sweden)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Scientists in Creative Biolabs are able to develop genetic, biological and chemical methods for BsAb engineering in immunology, and have established a comprehensive target cell-BsAb-vector system to deliver any other therapeutic gene to the target cell.
Not only can we say with a fair degree of confidence that, at the very least, self-neglect played a part, but we can say with absolute certainty that there "reasonable cause for concern about how BSAB, its partners or others worked together to safeguard the adult".
Antibody engineering technology for production of alternative bsAbs to design more efficient ADCs (bsADCs) has been proven in several preclinical models (156,157,159).
'We are very excited about our partnership with I-Mab to develop First-in-Class and Best-in-Class BsAbs and our collaboration will accelerate the development of innovative immunotherapy,' said Sang Hoon Lee, the founder and CEO of ABL Bio.
Alan Lotinga, chair of BSAB, said: "The evidence nationally and locally suggests this is a growing problem.
Both firms also agreed on a collaboration to co-develop additional BsAbs as part of the partnership.
Alan Lotinga, chair of BSAB, said: "This year's campaign is especially important as we are focusing on safeguarding vulnerable adults who have been befriended by people with the intention to abuse or commit a crime.
Under a cost-sharing product development collaboration, TRACON will be responsible for the regulatory and clinical development of TJD5 plus up to five of the BsAbs in North America, with the majority of the development effort expected to occur in the US.
However, the inadequacies of monovalent antibodies have been overcome by the advent of bispecific antibodies (bsAbs) with dual antigenic specificities, which are capable of simultaneously interacting with multiple receptors and/or ligands [99].
Currently, there are bispecific antibodies (BsAbs) that use the CD89 to target cells with cancer therapeutic agents.
The Bonn Scale (BSABS) is used for the assessment of basic symptoms, (17) while the Schizophrenia Proneness Instrument (SPI-A) (18) and the Examination of Anomalous Self Experience (EASE) (19) are useful aids in identifying minimal changes in subjective experience and for longitudinal monitoring (Table 2).